535 related articles for article (PubMed ID: 24420538)
1. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
Koid SS; Ziogas J; Campbell DJ
Hypertension; 2014 Apr; 63(4):768-73. PubMed ID: 24420538
[TBL] [Abstract][Full Text] [Related]
2. [Mechanism of cardioprotection against ischemia/reperfusion injury by valsartan: an experiment with isolated rat hearts].
Zhang YJ; Bai XJ; Qi ZM; Wang HX
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(47):3350-3. PubMed ID: 16409843
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice.
Abadir PM; Carey RM; Siragy HM
Hypertension; 2003 Oct; 42(4):600-4. PubMed ID: 12953015
[TBL] [Abstract][Full Text] [Related]
4. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
Moniwa N; Varagic J; Ahmad S; VonCannon JL; Simington SW; Wang H; Groban L; Brosnihan KB; Nagata S; Kato J; Kitamura K; Gomez RA; Lopez ML; Ferrario CM
Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of cyclic GMP production via AT2 and B2 receptors in the pressure-overloaded aorta after banding.
Hiyoshi H; Yayama K; Takano M; Okamoto H
Hypertension; 2004 Jun; 43(6):1258-63. PubMed ID: 15123575
[TBL] [Abstract][Full Text] [Related]
6. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice.
Yamamoto E; Kataoka K; Dong YF; Nakamura T; Fukuda M; Tokutomi Y; Matsuba S; Nako H; Nakagata N; Kaneko T; Ogawa H; Kim-Mitsuyama S
Hypertension; 2009 Sep; 54(3):633-8. PubMed ID: 19597038
[TBL] [Abstract][Full Text] [Related]
7. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.
Liu YH; Yang XP; Sharov VG; Nass O; Sabbah HN; Peterson E; Carretero OA
J Clin Invest; 1997 Apr; 99(8):1926-35. PubMed ID: 9109437
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotection against retinal ischemia-reperfusion injury by blocking the angiotensin II type 1 receptor.
Fukuda K; Hirooka K; Mizote M; Nakamura T; Itano T; Shiraga F
Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3629-38. PubMed ID: 20164447
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of the cardioprotective effect of inhibition of the renin-angiotensin system on ischemia/reperfusion-induced myocardial injury.
Wang LX; Ideishi M; Yahiro E; Urata H; Arakawa K; Saku K
Hypertens Res; 2001 Mar; 24(2):179-87. PubMed ID: 11325078
[TBL] [Abstract][Full Text] [Related]
10. Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.
Higashikuni Y; Takaoka M; Iwata H; Tanaka K; Hirata Y; Nagai R; Sata M
Hypertens Res; 2012 Jan; 35(1):62-9. PubMed ID: 21833001
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis.
Chrysant SG; Murray AV; Hoppe UC; Dattani D; Patel S; Hsu H; Zhang J
Curr Med Res Opin; 2008 Apr; 24(4):1039-47. PubMed ID: 18307835
[TBL] [Abstract][Full Text] [Related]
12. Flow-dependent dilation mediated by endogenous kinins requires angiotensin AT2 receptors.
Bergaya S; Hilgers RH; Meneton P; Dong Y; Bloch-Faure M; Inagami T; Alhenc-Gelas F; Lévy BI; Boulanger CM
Circ Res; 2004 Jun; 94(12):1623-9. PubMed ID: 15131008
[TBL] [Abstract][Full Text] [Related]
13. Aliskiren increases bradykinin and tissue kallikrein mRNA levels in the heart.
Campbell DJ; Zhang Y; Kelly DJ; Gilbert RE; McCarthy DJ; Shi W; Smyth GK
Clin Exp Pharmacol Physiol; 2011 Sep; 38(9):623-31. PubMed ID: 21736602
[TBL] [Abstract][Full Text] [Related]
14. A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren.
Wu WP; Chang CH; Chiu YT; Ku CL; Wen MC; Shu KH; Wu MJ
Am J Physiol Renal Physiol; 2010 Nov; 299(5):F929-41. PubMed ID: 20685818
[TBL] [Abstract][Full Text] [Related]
15. Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice.
Ye Y; Qian J; Castillo AC; Perez-Polo JR; Birnbaum Y
Cardiovasc Drugs Ther; 2011 Dec; 25(6):505-15. PubMed ID: 21987107
[TBL] [Abstract][Full Text] [Related]
16. Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia.
Messadi-Laribi E; Griol-Charhbili V; Pizard A; Vincent MP; Heudes D; Meneton P; Alhenc-Gelas F; Richer C
J Pharmacol Exp Ther; 2007 Oct; 323(1):210-6. PubMed ID: 17636004
[TBL] [Abstract][Full Text] [Related]
17. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
Azizi M; Ménard J; Bissery A; Guyene TT; Bura-Rivière A
Clin J Am Soc Nephrol; 2007 Sep; 2(5):947-55. PubMed ID: 17702736
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valasartan.
Hayashi N; Fujimura Y; Yamamoto S; Kometani M; Nakao K
Arzneimittelforschung; 1997 May; 47(5):625-9. PubMed ID: 9205776
[TBL] [Abstract][Full Text] [Related]
19. Beneficial cardiac effects of the renin inhibitor aliskiren in spontaneously hypertensive rats.
van Esch JH; Moltzer E; van Veghel R; Garrelds IM; Leijten F; Bouhuizen AM; Danser AH
J Hypertens; 2010 Oct; 28(10):2145-55. PubMed ID: 20625318
[TBL] [Abstract][Full Text] [Related]
20. Bradykinin B(2) receptor does not contribute to blood pressure lowering during AT(1) receptor blockade.
LeFebvre J; Shintani A; Gebretsadik T; Petro JR; Murphey LJ; Brown NJ
J Pharmacol Exp Ther; 2007 Mar; 320(3):1261-7. PubMed ID: 17182977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
